Catalyst Pharmaceuticals announced that its sub-licensee in Japan, DyDo Pharma, has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo’s New Drug Application to commercialize FIRDAPSE Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPRX:
- Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
- Catalyst Pharmaceuticals price target raised to $30 from $26 at H.C. Wainwright
- Catalyst Pharmaceuticals price target raised to $30 from $25 at Truist
- Catalyst Pharmaceuticals price target raised to $31 from $27 at Citi
- Catalyst Pharmaceuticals backs FY24 revenue view $455M-$475M,